HK1071363A1 - - Google Patents

Info

Publication number: HK1071363A1
Authority: HK; Hong Kong

Application number

HK05104120.0A

Inventor

Ian Bruce

Peter Finan

Catherine Leblanc

Clive Mccarthy

Lewis Whitehead

Nicola Elaine Press

Graham Charles Bloomfield

Judy Hayler

Louise Kirman

Mrinalini Sachin Oza

Lena Shukla

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-02-28

Filing date

2005-05-17

Publication date

2005-07-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27767104&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1071363(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-02-28 Priority claimed from GB0204765A external-priority patent/GB0204765D0/en

2002-12-19 Priority claimed from GB0229626A external-priority patent/GB0229626D0/en

2003-02-27 Priority to EP10174528A priority Critical patent/EP2311818B1/en

2005-05-17 Application filed by Novartis Ag filed Critical Novartis Ag

2005-05-17 Priority to HK11109515.4A priority patent/HK1155171A1/xx

2005-07-15 Publication of HK1071363A1 publication Critical patent/HK1071363A1/xx

2013-04-16 Priority to CY20131100312T priority patent/CY1114083T1/el

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Virology (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Neurology (AREA)
Communicable Diseases (AREA)
Otolaryngology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)
Oncology (AREA)
Neurosurgery (AREA)
Biotechnology (AREA)
Tropical Medicine & Parasitology (AREA)
Biomedical Technology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)

HK05104120.0A 2002-02-28 2005-05-17 HK1071363A1 (xx)

Priority Applications (3)

Application Number	Priority Date	Filing Date	Title
EP10174528A EP2311818B1 (en)	2002-02-28	2003-02-27	Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug
HK11109515.4A HK1155171A1 (en)	2002-02-28	2005-05-17	Combination of a 5-phenylthiazole compound as pi3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug
CY20131100312T CY1114083T1 (el)	2002-02-28	2013-04-16	Συνδυασμος μιας ενωσης της 5-φαινυλοθειαζολης ως αναστολεας της κινασης pi3 με ενα αντιφλεγμονωδες, βρογχοδιασταλτικο ή αντιισταμινικο φαρμακo

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0204765A GB0204765D0 (en)	2002-02-28	2002-02-28	Organic compounds
GB0229626A GB0229626D0 (en)	2002-12-19	2002-12-19	Organic compounds
PCT/EP2003/002036 WO2003072557A1 (en)	2002-02-28	2003-02-27	5-phenylthiazole derivatives and use as pi3 kinase inhibitors

Publications (1)

Publication Number	Publication Date
HK1071363A1 true HK1071363A1 (xx)	2005-07-15

Family

ID=27767104

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK05104120.0A HK1071363A1 (xx)	2002-02-28	2005-05-17

Country Status (28)

Country	Link
US (2)	US7687637B2 (xx)
EP (1)	EP1480962B1 (xx)
JP (2)	JP4408701B2 (xx)
KR (1)	KR100688370B1 (xx)
CN (1)	CN100548996C (xx)
AR (1)	AR038703A1 (xx)
AT (1)	ATE521598T1 (xx)
AU (1)	AU2003214080A1 (xx)
BR (1)	BR0308030A (xx)
CA (1)	CA2477601C (xx)
CO (1)	CO5611131A2 (xx)
CY (2)	CY1112084T1 (xx)
DK (2)	DK1480962T3 (xx)
EC (2)	ECSP045253A (xx)
ES (2)	ES2405816T3 (xx)
HK (1)	HK1071363A1 (xx)
IL (2)	IL163691A0 (xx)
MX (1)	MXPA04008362A (xx)
MY (1)	MY156407A (xx)
NO (1)	NO329175B1 (xx)
NZ (1)	NZ534657A (xx)
PE (1)	PE20030968A1 (xx)
PL (2)	PL219449B1 (xx)
PT (2)	PT1480962E (xx)
RU (2)	RU2378263C2 (xx)
SI (1)	SI1480962T1 (xx)
TW (1)	TWI314928B (xx)
WO (1)	WO2003072557A1 (xx)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR9914465A (pt)	1998-09-29	2001-10-09	Gamida Cell Ltd	Métodos para controlar a proliferação e a diferenciação de células-tronco e células progenitoras e uma composição farmacêutica para induzir a diferenciação em uma população de células
IL152904A0 (en)	2002-01-24	2003-06-24	Gamida Cell Ltd	Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
WO2003062404A1 (en)	2002-01-25	2003-07-31	Gamida-Cell Ltd.	Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
US7265138B2 (en)	2003-02-10	2007-09-04	Amgen Inc.	Vanilloid receptor ligands and their use in treatments
GB0305152D0 (en)	2003-03-06	2003-04-09	Novartis Ag	Organic compounds
WO2004087138A1 (en) *	2003-03-31	2004-10-14	Sucampo Ag	Method for treating vascular hyperpermeable disease
TW200519106A (en)	2003-05-02	2005-06-16	Novartis Ag	Organic compounds
GB0320197D0 (en)	2003-08-28	2003-10-01	Novartis Ag	Organic compounds
ES2287896T3 (es) *	2004-01-12	2007-12-16	Laboratoires Serono Sa	Derivados de tiazol y uso de los mismos.
CN102796081B (zh)	2004-08-28	2015-04-22	阿斯利康(瑞典)有限公司	作为趋化因子受体调节剂的嘧啶磺酰胺衍生物
KR20070064660A (ko)	2004-10-07	2007-06-21	베링거 인겔하임 인터내셔날 게엠베하	Ｐｉ３ 키나제
UY29149A1 (es) *	2004-10-07	2006-05-31	Boehringer Ingelheim Int	Tiazolil-dihidro-indazoles
SE0402735D0 (sv) *	2004-11-09	2004-11-09	Astrazeneca Ab	Novel compounds
JP2008542196A (ja) *	2005-05-05	2008-11-27	クロマセラピューティクスリミテッド	カルボキシルエステラーゼにより加水分解可能なアルファアミノ酸エステル−薬剤複合体
CN101248054B (zh) *	2005-05-24	2012-05-09	默克雪兰诺有限公司	噻唑衍生物及其应用
ZA200710104B (en)	2005-05-24	2009-03-25	Serono Lab	Thiazole derivatives and use thereof
US8846393B2 (en)	2005-11-29	2014-09-30	Gamida-Cell Ltd.	Methods of improving stem cell homing and engraftment
WO2007064891A1 (en) *	2005-12-01	2007-06-07	The Scripps Research Institute	Compositions and methods for inducing neuronal differentiation
GB0525671D0 (en) *	2005-12-16	2006-01-25	Novartis Ag	Organic compounds
BRPI0706621A2 (pt) *	2006-01-18	2011-04-05	Amgen Inc	composto, composição farmacêutica, métodos para tratar um distúrbio mediado por quinase em um mamìfero e para tratar um distúrbio relacionado com a proliferação em um mamìfero, e , uso do composto
JP2009523748A (ja) *	2006-01-18	2009-06-25	シエナビオテクソシエタペルアチオニ	α７ニコチン性アセチルコリン受容体の調節物質およびそれらの治療への使用
JP2009523769A (ja) *	2006-01-23	2009-06-25	ラボラトワールセローノソシエテアノニム	チアゾール誘導体及びこれらの使用
US7517995B2 (en) *	2006-04-06	2009-04-14	Boehringer Ingelheim International Gmbh	Thiazolyl-dihydro-cyclopentapyrazole
US20070238746A1 (en) *	2006-04-06	2007-10-11	Trixi Brandl	Thiazolyl-dihydro-chinazoline
US7691868B2 (en)	2006-04-06	2010-04-06	Boehringer Ingelheim International Gmbh	Thiazolyl-dihydro-quinazoline
EP2016075A1 (en) *	2006-05-03	2009-01-21	AstraZeneca AB	Thiazole derivatives and their use as anti-tumour agents
GB0608854D0 (en) *	2006-05-04	2006-06-14	Chroma Therapeutics Ltd	P13 kinase inhibitors
GB0608823D0 (en) *	2006-05-04	2006-06-14	Chroma Therapeutics Ltd	Inhibitors of P13 kinase
GB0610243D0 (en)	2006-05-23	2006-07-05	Novartis Ag	Organic compounds
GB0612630D0 (en) *	2006-06-26	2006-08-02	Novartis Ag	Organic compounds
EP1887359B1 (en)	2006-08-03	2008-11-12	Cellzome Ag	Methods for the identification of PI3K interacting molecules and for the purification of PI3K
CA2662196A1 (en) *	2006-09-01	2008-03-06	Vertex Pharmaceuticals Incorporated	Inhibitors of phosphatidylinositol 3-kinase
CN101636155A (zh) *	2006-11-29	2010-01-27	艾博特公司	二酰甘油o-酰基转移酶1型酶的抑制剂
PE20090717A1 (es) *	2007-05-18	2009-07-18	Smithkline Beecham Corp	Derivados de quinolina como inhibidores de la pi3 quinasa
IN2009KN04568A (xx)	2007-06-01	2015-08-28	Univ Princeton
US7919504B2 (en) *	2007-07-17	2011-04-05	Amgen Inc.	Thiadiazole modulators of PKB
US7897619B2 (en)	2007-07-17	2011-03-01	Amgen Inc.	Heterocyclic modulators of PKB
JP2011506560A (ja)	2007-12-20	2011-03-03	ノバルティスアーゲー	Ｐｉ３キナーゼ阻害剤として用いられるチアゾール誘導体
US20110111972A1 (en)	2008-02-04	2011-05-12	Cellzome Ag	Selectivity profiling of pi3k interacting molecules against multiple targets
UA104147C2 (uk)	2008-09-10	2014-01-10	Новартис Аг	Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
CN101684106B (zh) *	2008-09-22	2013-06-12	北京摩力克科技有限公司	噻唑鎓盐类化合物及其治疗蛋白老化相关疾病的用途
PL2404908T3 (pl) *	2009-02-27	2014-12-31	Teijin Ltd	Sposób wytwarzania podstawionej fenylem pochodnej heterocyklicznej przez sprzężenie z użyciem katalizatora metalu przejściowego
EP2426135A4 (en) *	2009-04-27	2013-02-20	Shionogi & Co	UREA DERIVATIVE WITH PI3K-INHIBITING EFFECT
CN102471351A (zh)	2009-07-02	2012-05-23	诺瓦提斯公司	用作pi3k抑制剂的2-羧酰胺环氨基脲
US8293753B2 (en)	2009-07-02	2012-10-23	Novartis Ag	Substituted 2-carboxamide cycloamino ureas
GB0913345D0 (en)	2009-07-31	2009-09-16	Astrazeneca Ab	New combination 802
JPWO2011048936A1 (ja)	2009-10-19	2013-03-07	大正製薬株式会社	アミノチアゾール誘導体
WO2011061527A1 (en)	2009-11-17	2011-05-26	Astrazeneca Ab	Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
US9555033B2 (en)	2010-02-03	2017-01-31	Signal Pharmaceuticals, Llc	Identification of LKB1 mutation as a predictive biomarker for sensitivity to TOR kinase inhibitors
GB2485886A (en) *	2010-11-24	2012-05-30	Lithera Inc	Injectable formulations comprising a lipophilic glucocorticosteroid for regional adiposity reduction
GB201021992D0 (en)	2010-12-23	2011-02-02	Astrazeneca Ab	Compound
GB201021979D0 (en)	2010-12-23	2011-02-02	Astrazeneca Ab	New compound
WO2013019927A1 (en)	2011-08-03	2013-02-07	Signal Pharmaceuticals, Llc	Identification of gene expression profile as a predictive biomarker for lkb1 status
WO2013052845A1 (en)	2011-10-05	2013-04-11	The Board Of Trustees Of The Leland Stanford Junior University	Pi-kinase inhibitors with broad spectrum anti-infective activity
US9926309B2 (en)	2011-10-05	2018-03-27	The Board Of Trustees Of The Leland Stanford Junior University	Pi-kinase inhibitors with anti-infective activity
EP2814951B1 (en)	2012-02-13	2019-04-03	Gamida-Cell Ltd.	Culturing of mesenchymal stem cells
US9567569B2 (en)	2012-07-23	2017-02-14	Gamida Cell Ltd.	Methods of culturing and expanding mesenchymal stem cells
US9175266B2 (en)	2012-07-23	2015-11-03	Gamida Cell Ltd.	Enhancement of natural killer (NK) cell proliferation and activity
AU2013203714B2 (en)	2012-10-18	2015-12-03	Signal Pharmaceuticals, Llc	Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
AU2014254050B2 (en)	2013-04-17	2018-10-04	Signal Pharmaceuticals, Llc	Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
MY189663A (en)	2013-04-17	2022-02-23	Signal Pharm Llc	Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
TWI631949B (zh)	2013-04-17	2018-08-11	標誌製藥公司	使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
MX2015014455A (es)	2013-04-17	2016-07-21	Signal Pharm Llc	Terapia de combinacion que comprende un inhibidor de tor cinasa y n-(3-(5-fluoro-2-(4-(2-metoxietoxi)fenilamino)pirimidin-4-ilamino )fenil)acrilamida para tratar cancer.
MX2015014590A (es)	2013-04-17	2016-03-03	Signal Pharm Llc	Tratamiento de cancer con dihidropirazino-pirazinas.
EP2986322A1 (en)	2013-04-17	2016-02-24	Signal Pharmaceuticals, LLC	Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
AU2014254052B2 (en)	2013-04-17	2019-06-06	Signal Pharmaceuticals, Llc	Treatment of cancer with dihydropyrazino-pyrazines
MX2015015880A (es)	2013-05-29	2016-05-31	Signal Pharm Llc	Composiciones farmaceuticas de 7-(6-(2-hidroxipropan-2-il)piridin- 3-il)-1-((trans)-4-metoxiciclohexil)-3,4-dihidropirazino[2,3-b]pi razin-2(1h)-ona, una forma solida del mismo y metodos de su uso.
CN104418858B (zh)	2013-08-30	2018-12-11	浙江医药股份有限公司新昌制药厂	2,6-二含氮取代的嘌呤衍生物及其制备方法和其药物组合物与应用
DE102013226711A1 (de) *	2013-12-19	2015-06-25	Beiersdorf Ag	Verwendung von Alkylamidothiazolen in kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe vor und Behandlung von sensibler Haut
NZ714742A (en)	2014-04-16	2017-04-28	Signal Pharm Llc	Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
EP3131551A4 (en)	2014-04-16	2017-09-20	Signal Pharmaceuticals, LLC	SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
WO2015162584A1 (en)	2014-04-24	2015-10-29	Novartis Ag	Crystalline forms of the sulfate salt of n-[5-(3-imidazol-1-yl-4-methanesulfonyl-phenyl)-4-methyl-thiazol-2-yl]-acetamide
WO2016065583A1 (en)	2014-10-30	2016-05-06	Merck Sharp & Dohme Corp.	Oxazole orexin receptor antagonists
BR112018003516B8 (pt) *	2015-09-04	2022-08-23	Dow Agrosciences Llc	Moléculas, composição pesticida, e processos para controlar uma praga
CN108137489B (zh) *	2015-09-04	2020-11-20	美国陶氏益农公司	具有杀虫效用的分子，以及与其相关的中间体、组合物和方法
NZ739853A (en) *	2015-09-10	2018-11-30	Dow Agrosciences Llc	Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto
EP3872068A1 (en) *	2015-12-16	2021-09-01	Nippon Soda Co., Ltd.	Arylazole compound and pest control agent
WO2017132746A1 (en)	2016-02-01	2017-08-10	The Governing Council Of The University Of Toronto	53bp1 inhibitors
US11091472B2 (en)	2016-02-26	2021-08-17	The Regents Of The University Of California	PI-kinase inhibitors with anti-infective activity
CN110996955A (zh)	2017-06-22	2020-04-10	细胞基因公司	以乙型肝炎病毒感染为特征的肝细胞癌的治疗
WO2019101871A1 (en) *	2017-11-23	2019-05-31	Inserm (Institut National De La Sante Et De La Recherche Medicale)	A new marker for predicting the sensitivity to pi3k inhibitors
AU2020241869A1 (en) *	2019-03-21	2021-11-18	The Board Of Trustees Of The Leland Stanford Junior University	PI4-kinase inhibitors and methods of using the same
CN115028596B (zh) *	2021-03-03	2024-06-07	帕潘纳(北京)科技有限公司	制备苯唑草酮中间体的方法
WO2024137533A1 (en)	2022-12-19	2024-06-27	Graphite Bio, Inc.	Improved peptide inhibitors of p53 binding protein 53bp1

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB951885A (en) *	1961-05-13	1964-03-11	Sankyo Co	A new process for the preparation of thiazole compounds
OA01933A (fr)	1965-04-06	1970-02-04	Pechiney Saint Gobain	Dérivés du thiazole.
US3749775A (en) *	1969-07-07	1973-07-31	Stauffer Chemical Co	Insecticidal 2-aminothiazole phosphates and phosphonates
FR2429210A1 (fr)	1978-06-19	1980-01-18	Fabre Sa Pierre	Derives de phenyl-4 thiazolyl-2 oxamates utiles dans le traitement de l'asthme
US4511574A (en)	1981-01-08	1985-04-16	Mitsui Toatsu Kagaku Kabushiki Kaisha	N-(4-Phenyl-2-thiazolyl)carbamate derivatives
JPS57136579A (en)	1981-01-21	1982-08-23	Mitsui Toatsu Chem Inc	Thiazolylurea derivative, its preparation, and pharmaceutical composition containing the same
DE3413755A1 (de)	1984-04-12	1985-10-24	Basf Ag, 6700 Ludwigshafen	Thiazolylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
JPH0725754B2 (ja) *	1986-01-30	1995-03-22	富山化学工業株式会社	新規なチアゾール化合物またはその塩
DE3864248D1 (de)	1987-12-14	1991-09-19	Sawai Seiyaku Kk	Carboxamide mit tetrazol- und thiazol-ringen und ihre anwendung.
US4891375A (en)	1988-01-13	1990-01-02	Pfizer Inc.	Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds
WO1992009586A1 (en)	1990-11-30	1992-06-11	Otsuka Pharmaceutical Co., Ltd.	Active oxygen inhibitor
DE4401911A1 (de)	1994-01-24	1995-08-03	Basf Ag	Verwendung von Aryl- oder Heteroarylazoanilinen in der nichtlinearen Optik
JPH10504542A (ja)	1994-07-27	1998-05-06	ジー．ディー．サールアンドカンパニー	炎症処置用の置換チアゾール化合物
DE69526958T2 (de) *	1994-11-29	2003-01-16	Hisamitsu Pharmaceutical Co., Inc.	Antibakterielle oder bakterizide mittel, die 2-aminothiazolderivate und deren salze enthalten
GB9625843D0 (en) *	1996-12-12	1997-01-29	Merck & Co Inc	Phenyl spiroethercycloalkyl tachykinn receptor antagonists
HUP0101704A3 (en)	1997-12-22	2002-12-28	Bayer Corp Pittsburgh	Kinease substituted heterocyclic ureas with raf inhibition activity and pharmaceutical compositions containing them
EP0928790B1 (en) *	1998-01-02	2003-03-05	F. Hoffmann-La Roche Ag	Thiazole derivatives
US6100282A (en) *	1998-01-02	2000-08-08	Hoffman-La Roche Inc.	Thiazole derivatives
US6043254A (en)	1998-04-03	2000-03-28	Boehringer Ingelheim Pharma Kg	Indolinones having kinase-inhibiting activity
GB9823873D0 (en) *	1998-10-30	1998-12-30	Pharmacia & Upjohn Spa	2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
AU2001230426C1 (en)	2000-01-24	2006-06-22	Astrazeneca Ab	Therapeutic morpholino-substituted compounds
NZ522076A (en)	2000-04-25	2005-08-26	Icos Corp	Inhibitors of human phosphatidyl-inositol 3-kinase delta
PL365170A1 (en)	2000-07-26	2004-12-27	Bristol-Myers Squibb Company	N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases
CN101125138A (zh)	2000-12-18	2008-02-20	株式会社医药分子设计研究所	炎症性细胞因子产生游离抑制剂
AR039059A1 (es)	2001-08-06	2005-02-09	Sanofi Aventis	Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
US20040242637A1 (en) *	2001-08-17	2004-12-02	Hartman George D	Tyrosine kinase inhibitors
US6812653B2 (en) *	2002-07-26	2004-11-02	Richard S. Bellivean	Method and apparatus for controlling images with image projection lighting devices
GB0525671D0 (en) *	2005-12-16	2006-01-25	Novartis Ag	Organic compounds

2003
- 2003-02-26 AR ARP030100626A patent/AR038703A1/es active IP Right Grant
- 2003-02-26 TW TW092104036A patent/TWI314928B/zh not_active IP Right Cessation
- 2003-02-26 MY MYPI20030662A patent/MY156407A/en unknown
- 2003-02-26 PE PE2003000188A patent/PE20030968A1/es not_active Application Discontinuation
- 2003-02-27 NZ NZ534657A patent/NZ534657A/en not_active IP Right Cessation
- 2003-02-27 KR KR1020047013419A patent/KR100688370B1/ko not_active IP Right Cessation
- 2003-02-27 WO PCT/EP2003/002036 patent/WO2003072557A1/en active Application Filing
- 2003-02-27 EP EP03709730A patent/EP1480962B1/en not_active Expired - Lifetime
- 2003-02-27 AU AU2003214080A patent/AU2003214080A1/en not_active Abandoned
- 2003-02-27 SI SI200332074T patent/SI1480962T1/sl unknown
- 2003-02-27 PL PL403456A patent/PL219449B1/pl unknown
- 2003-02-27 AT AT03709730T patent/ATE521598T1/de active
- 2003-02-27 BR BR0308030-7A patent/BR0308030A/pt not_active IP Right Cessation
- 2003-02-27 DK DK03709730.0T patent/DK1480962T3/da active
- 2003-02-27 ES ES10174528T patent/ES2405816T3/es not_active Expired - Lifetime
- 2003-02-27 DK DK10174528.9T patent/DK2311818T3/da active
- 2003-02-27 JP JP2003571263A patent/JP4408701B2/ja not_active Expired - Fee Related
- 2003-02-27 ES ES03709730T patent/ES2372597T3/es not_active Expired - Lifetime
- 2003-02-27 CA CA2477601A patent/CA2477601C/en not_active Expired - Fee Related
- 2003-02-27 US US10/504,259 patent/US7687637B2/en not_active Expired - Fee Related
- 2003-02-27 MX MXPA04008362A patent/MXPA04008362A/es active IP Right Grant
- 2003-02-27 PT PT03709730T patent/PT1480962E/pt unknown
- 2003-02-27 RU RU2004129279/04A patent/RU2378263C2/ru not_active IP Right Cessation
- 2003-02-27 RU RU2009132712/04A patent/RU2436780C2/ru not_active IP Right Cessation
- 2003-02-27 IL IL16369103A patent/IL163691A0/xx unknown
- 2003-02-27 CN CNB038047969A patent/CN100548996C/zh not_active Expired - Fee Related
- 2003-02-27 PT PT101745289T patent/PT2311818E/pt unknown
- 2003-02-27 PL PL370575A patent/PL215581B1/pl unknown
2004
- 2004-08-23 IL IL163691A patent/IL163691A/en not_active IP Right Cessation
- 2004-08-28 EC EC2004005253A patent/ECSP045253A/es unknown
- 2004-09-15 CO CO04091790A patent/CO5611131A2/es active IP Right Grant
- 2004-09-27 NO NO20044095A patent/NO329175B1/no not_active IP Right Cessation
2005
- 2005-05-17 HK HK05104120.0A patent/HK1071363A1/xx not_active IP Right Cessation
2009
- 2009-08-12 JP JP2009187248A patent/JP2009298799A/ja active Pending
- 2009-12-17 US US12/640,479 patent/US8129541B2/en not_active Expired - Fee Related
2010
- 2010-08-30 EC EC2010005253A patent/ECSP105253A/es unknown
2011
- 2011-11-24 CY CY20111101144T patent/CY1112084T1/el unknown
2013
- 2013-04-16 CY CY20131100312T patent/CY1114083T1/el unknown

Also Published As

Publication number	Publication date
PL370575A1 (en)	2005-05-30
MY156407A (en)	2016-02-26
DK2311818T3 (da)	2013-05-06
ES2405816T3 (es)	2013-06-03
CN1639139A (zh)	2005-07-13
US20100093690A1 (en)	2010-04-15
RU2378263C2 (ru)	2010-01-10
TWI314928B (en)	2009-09-21
CY1114083T1 (el)	2016-07-27
SI1480962T1 (sl)	2011-12-30
BR0308030A (pt)	2004-12-28
MXPA04008362A (es)	2004-11-26
EP1480962A1 (en)	2004-12-01
JP2009298799A (ja)	2009-12-24
CA2477601A1 (en)	2003-09-04
KR100688370B1 (ko)	2007-03-02
NO329175B1 (no)	2010-09-06
NO20044095L (no)	2004-11-02
RU2436780C2 (ru)	2011-12-20
PL403456A1 (pl)	2013-05-27
ES2372597T3 (es)	2012-01-24
CA2477601C (en)	2011-05-24
PL215581B1 (pl)	2013-12-31
RU2009132712A (ru)	2011-03-10
ATE521598T1 (de)	2011-09-15
PE20030968A1 (es)	2004-01-12
IL163691A (en)	2010-11-30
PL219449B1 (pl)	2015-04-30
CO5611131A2 (es)	2006-02-28
ECSP045253A (es)	2004-09-28
IL163691A0 (en)	2005-12-18
AR038703A1 (es)	2005-01-26
TW200303750A (en)	2003-09-16
EP1480962B1 (en)	2011-08-24
RU2004129279A (ru)	2005-06-27
US20050119320A1 (en)	2005-06-02
US8129541B2 (en)	2012-03-06
NZ534657A (en)	2007-05-31
WO2003072557A1 (en)	2003-09-04
DK1480962T3 (da)	2011-12-05
AU2003214080A1 (en)	2003-09-09
CY1112084T1 (el)	2015-11-04
PT2311818E (pt)	2013-05-15
PT1480962E (pt)	2011-12-15
JP2005522458A (ja)	2005-07-28
CN100548996C (zh)	2009-10-14
KR20040091674A (ko)	2004-10-28
ECSP105253A (es)	2010-09-30
US7687637B2 (en)	2010-03-30
JP4408701B2 (ja)	2010-02-03

Publication	Publication Date	Title
BE2019C547I2 (xx)	2022-05-17
BE2019C510I2 (xx)	2022-05-19
BE2018C021I2 (xx)	2023-03-07
BE2017C049I2 (xx)	2022-08-09
BE2017C005I2 (xx)	2022-05-17
BE2016C069I2 (xx)	2022-05-17
BE2016C040I2 (xx)	2022-05-17
BE2016C013I2 (xx)	2022-05-17
BE2015C078I2 (xx)	2022-08-09
BE2016C002I2 (xx)	2023-03-07
BE2018C018I2 (xx)	2023-03-07
BE2015C017I2 (xx)	2022-09-22
BE2014C053I2 (xx)	2022-08-30
BE2014C051I2 (xx)	2022-08-09
BE2014C041I2 (xx)	2022-08-09
BE2014C030I2 (xx)	2022-08-09
BE2014C016I2 (xx)	2023-03-07
BE2014C015I2 (xx)	2022-08-09
BE2013C063I2 (xx)	2023-03-07
BE2013C039I2 (xx)	2023-03-07
FR13C0032I1 (xx)	2013-08-09
BE2011C038I2 (xx)	2022-08-09
JP2003157229A5 (xx)	2006-07-06
BE2015C068I2 (xx)	2024-08-08
BRPI0215435A2 (xx)	2004-12-14

Legal Events

Date	Code	Title	Description
2016-09-23	PC	Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)	Effective date: 20160227